TherapeuticsMD (TXMD) Cash from Investing Activities (2011 - 2022)

TherapeuticsMD has reported Cash from Investing Activities for 12 years, with the latest figure at -$74000.0 in Q4 2022.

• For the quarter ending Q4 2022, Cash from Investing Activities rose 95.11% year-over-year to -$74000.0; the trailing twelve-month figure through Dec 2022 stood at -$355000.0 (up 84.03% YoY), and the FY2022 full-year result was -$355000.0, up 84.03% from the prior year.
• Cash from Investing Activities for Q4 2022 stood at -$74000.0, down from $7000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $7000.0 in Q3 2022, with the low at -$20.7 million in Q4 2019.
• Historically, Cash from Investing Activities has averaged -$2.5 million across 5 years, with a median of -$418500.0 in 2020.
• Annual changes were most pronounced in 2018 — Cash from Investing Activities plunged 28077.04% — and 2022, when it jumped 103.85%.
• TherapeuticsMD's Cash from Investing Activities stood at -$671171.0 in 2018, then sank by 2986.19% to -$20.7 million in 2019, then jumped by 97.62% to -$494000.0 in 2020, then slumped by 206.48% to -$1.5 million in 2021, then soared by 95.11% to -$74000.0 in 2022.
• The last three Cash from Investing Activities figures came in at -$74000.0 (Q4 2022), $7000.0 (Q3 2022), and -$76000.0 (Q2 2022), per Business Quant data.